Bill Text: IA SF282 | 2017-2018 | 87th General Assembly | Introduced
Bill Title: A bill for an act relating to the medical use of cannabidiol including the rescheduling of a cannabidiol investigational product approved as a prescription drug medication under federal law and including effective date provisions. (See SF 470.)
Sponsorship: Partisan Bill (Republican 1)
Status: (Introduced - Dead) 2017-03-02 - Subcommittee recommends passage. [SF282 Detail]
Download: Iowa-2017-SF282-Introduced.html
Senate File 282 - Introduced SENATE FILE BY ZAUN A BILL FOR 1 An Act relating to the medical use of cannabidiol including 2 the rescheduling of a cannabidiol investigational product 3 approved as a prescription drug medication under federal law 4 and including effective date provisions. 5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA: TLSB 2301XS (2) 87 rh/rj PAG LIN 1 1 Section 1. Section 124.201, Code 2017, is amended by adding 1 2 the following new subsection: 1 3 NEW SUBSECTION. 5. a. If a cannabidiol investigational 1 4 product approved as a prescription drug medication by the 1 5 United States food and drug administration is designated 1 6 as a schedule II controlled substance by the federal drug 1 7 enforcement agency, the board shall, upon notice of the 1 8 designation, similarly designate the prescription drug 1 9 medication as a schedule II controlled substance under this 1 10 chapter. Such designation by the board shall be immediately 1 11 effective upon the date of publication in the federal register 1 12 of the final order designating the prescription drug medication 1 13 as a schedule II controlled substance. 1 14 b. The board shall adopt rules pursuant to chapter 17A to 1 15 administer this subsection. The board may adopt rules on an 1 16 emergency basis as provided in section 17A.4, subsection 3, and 1 17 section 17A.5, subsection 2, to administer this subsection, 1 18 and the rules shall be effective immediately upon filing 1 19 unless a later date is specified in the rules. Any emergency 1 20 rules adopted in accordance with this subsection shall also be 1 21 published as a notice of intended action as provided in section 1 22 17A.4, subsection 1. 1 23 Sec. 2. REPEAL. Section 124D.8, Code 2017, is repealed. 1 24 Sec. 3. EFFECTIVE DATE. The section of this Act repealing 1 25 section 124D.8, Code 2017, takes effect June 30, 2017. 1 26 EXPLANATION 1 27 The inclusion of this explanation does not constitute agreement with 1 28 the explanation's substance by the members of the general assembly. 1 29 This bill relates to the medical use of cannabidiol, 1 30 including the rescheduling of a cannabidiol investigational 1 31 product approved as a prescription drug medication under 1 32 federal law. 1 33 The bill provides if a cannabidiol investigational product 1 34 approved as a prescription drug medication by the United States 1 35 food and drug administration is designated as a schedule II 2 1 controlled substance by the federal drug enforcement agency, 2 2 the board of pharmacy shall, upon notice of the designation, 2 3 similarly designate the prescription drug medication as 2 4 a schedule II controlled substance. Such designation by 2 5 the board shall be immediately effective upon the date 2 6 of publication in the federal register of the final order 2 7 designating the prescription drug medication as a schedule II 2 8 controlled substance. 2 9 The bill provides that the board shall adopt rules pursuant 2 10 to Code chapter 17A to administer the bill and may adopt 2 11 emergency rules which shall be effective immediately upon 2 12 filing unless a later date is specified in the rules. Any 2 13 emergency rules adopted shall also be published as a notice of 2 14 intended action as provided in Code section 17A.4, subsection 2 15 1. 2 16 The bill strikes the repeal of Code chapter 124D (medical 2 17 cannabidiol Act) before the repeal becomes effective July 1, 2 18 2017. LSB 2301XS (2) 87 rh/rj
